biostudies-literatureMayer-Blackwell KNational Institute of Allergy and Infectious DiseasesNIAID NIH HHSCenter for AIDS Research, Duke University983313https://www.ebi.ac.uk/biostudies/studies/S-EPMC9597301biostudies-literatureUnknown13Many participants in HIV-1 vaccine trials, who have not previously been exposed to or vaccinated against HIV-1, display serum immunoglobulin antibodies that bind the gp41 region of HIV-1 envelope prior to vaccination. Previous studies have hypothesized that these pre-existing antibodies may be cross-reactive and may skew future vaccine responses. In 12 large studies conducted by the HIV Vaccine Trial Network (HVTN) (n=1470 individuals), we find wide variation among participants in the pre-vaccine levels of gp41-reactive antibodies as measured by the binding antibody multiplex assay (BAMA). In the absence of exposure to the gp41 immunogen, anti-gp41 IgG levels were temporally stable over 26-52 weeks in repeated measures of placebo recipients. The analysis revealed that the geometric mean ofFrontiers in immunologyMulti-trial analysis of HIV-1 envelope gp41-reactive antibodies among global recipients of candidate HIV-1 vaccines.PMC9597301U01 AI068614U01 AI068635UM1 AI068635U01 AI068618UM1 AI068614P30 AI064518UM1 AI068618AI068618, AI068635, AI068614Potchen NHeptinstall JMinot SSSawant SMayer-Blackwell KKublin JGSeaton KShen XTomaras GDJohnson AMFiore-Gartland AfalseMulti-trial analysis of HIV-1 envelope gp41-reactive antibodies among global recipients of candidate HIV-1 vaccines.Many participants in HIV-1 vaccine trials, who have not previously been exposed to or vaccinated against HIV-1, display serum immunoglobulin antibodies that bind the gp41 region of HIV-1 envelope prior to vaccination. Previous studies have hypothesized that these pre-existing antibodies may be cross-reactive and may skew future vaccine responses. In 12 large studies conducted by the HIV Vaccine Trial Network (HVTN) (n=1470 individuals), we find wide variation among participants in the pre-vaccine levels of gp41-reactive antibodies as measured by the binding antibody multiplex assay (BAMA). In the absence of exposure to the gp41 immunogen, anti-gp41 IgG levels were temporally stable over 26-52 weeks in repeated measures of placebo recipients. The analysis revealed that the geometric mean of2022-01-01T00:00:00Z20222026-06-01T02:25:32.8Z2025-04-04T09:42:29.126ZS-EPMC95973013631172010.3389/fimmu.2022.983313